What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
about
Prescription trends of immunosuppressive drugs in post-heart transplant recipients in Taiwan, 2000-2009.Cardiac allograft vasculopathy: a donor or recipient induced pathology?Recombinant adenoviral gene transfer does not affect cardiac allograft vasculopathyClinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy.Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft vasculopathy.
P2860
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@ast
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@en
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@nl
type
label
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@ast
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@en
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@nl
prefLabel
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@ast
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@en
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@nl
P2860
P356
P1476
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
@en
P2093
Jon Kobashigawa
P2860
P2888
P304
P356
10.1186/CVM-1-3-166
P577
2000-01-01T00:00:00Z
P5875
P6179
1052147596